Andrew Aplin Named First Recipient of Kalbach-Newton Professorship in Cancer Research


Headshot of Andrew AplinThe Sidney Kimmel Medical College (SKMC) at Thomas Jefferson University (TJU) has established a new professorship, made possible through generous donations from the estates of Raymond B. Kalbach and Caroline Newton.

Mark Tykocinski, MD, Provost of TJU, and Anthony F. and Gertrude M. DePalma Dean of SKMC, has named Andrew E. Aplin, PhD, one of Jefferson’s leading cancer researchers, as the first recipient of the Kalbach-Newton Professorship in Cancer Research.

The investiture took place at Jefferson on February 13.

Aplin is Associate Director for Basic Research and leader of the Cancer Cell Biology and Signaling Program at the Sidney Kimmel Cancer Center (SKCC) at TJU. He is funded by the NIH/NCI to investigate skin melanoma and recently received a $1 million grant from the Dr. Ralph and Marian Falk Medical Research Trust for a team-based approach to investigate ocular melanoma.

Nationally, Aplin is a member of the grant review panel for the Melanoma Research Alliance and a member of the Scientific Advisory Council for the Melanoma Research Foundation. He is also Associate Editor of Pigment Cell & Melanoma Research and is on the editorial boards of Cancer Research and Molecular Cancer Research.

This honor recognizes the numerous discoveries Aplin has made in the melanoma field, along with his significant leadership, education, and mentoring roles at Jefferson over the years.

“Dr. Aplin excels at the frontier of melanoma research, and I look forward to his further contributions with this professorship,” said Karen Knudsen, PhD, Director of SKCC and Hilary Koprowski Professor and Chair, Department of Cancer Biology.